# SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Source: https://onco.cc/trials/nct06123494/  
OnCo record `nct06123494` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab rezetecan, Docetaxel and Ramucirumab in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen is a phase 3 interventional study registered as NCT06123494 by Jiangsu HengRui Medicine Co., Ltd., with 360 participants planned, started 2024-01-09 and due to reach its primary completion in 2027-06-30. Interventions recorded: SHR-A1811 and Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06123494
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open-label Study of SHR-A1811 (HER2-ADC) Compared With the Chemotherapy Treatment Chosen by the Investigators for Subjects With HER2-positive Metastatic and/or Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Who Have Progressed on or After First-line Anti-HER2 Therapy-containing Regimen
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT06123494: https://clinicaltrials.gov/study/NCT06123494

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06123494.json